The Breast cancer drugs market size in Kenya stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period
Breast cancer is the most commonly diagnosed cancer in Kenya, with an annual incidence of approximately 6,000 new cases and 2,500 cancer-related deaths. The rising incidence of cancer in Kenya may be attributed to increase in the ageing population, adoption of unhealth lifestyles, tobacco and alcohol consumption and physical inactivity. Rising cancer incidence and increased public concerns in Kenya led to the passing of the Cancer Control and Prevention Bill by Parliament in 2011, followed by publication of the national Cancer Control Strategy and increased investment in cancer diagnostic equipment. Yet, investments in cancer surveillance and registry activities to monitor and improve cancer control programs are limited.
Breast Cancer market is driven by the increasing prevalence of Breast Cancer in Kenya.
The Breast Cancer National Access Programme is a public-private partnership that aims at improving breast cancer care in Kenya. Access to medicine will be made available to patients seeking treatment at public institutions with the government of Kenya and Roche jointly covering the costs.
Increasing levels of awareness related to early diagnosis and screening of breast and cervical cancers in females and available therapies are leading to a high growth of Breast Cancer Drugs. Improvement in the diagnostic capabilities in the country will propel growth in the breast cancer drugs market in Kenya in the forecasted period.
However, the side effects caused by Chemotherapy and Immunotherapy are restraining market growth. Some of the products are withdrawn from the market due to serious side effects. Other restraints of market growth include high cost of treatment and oncology drugs. The National Hospital Insurance Fund (NHIF) provides only 25,000 Kenyan Shillings per patient towards cancer care.